Nature's Sunshine Products, Inc (NATR) Fair Value 2026

NATR · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.5 /10

32 fundamental signals · 13 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-07-13, Nature's Sunshine Products, Inc (NATR) trades at $21.58, approximately 34% above CirclFi’s Bayesian DCF fair value of $16.11. QOC: 8.5/10. Value Trap Risk: 12/100 (SAFE). 13/13 models active.

Key Facts

Ticker
NATR
Price
$21.58
Quality Score
8.5/10
Value Trap Risk
12/100
Models Active
13/13
Last Updated
Strength: Quality Score of 8.5/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Valuation Matrix

13 Intrinsic Value Models vs. Current Price ($21.58)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
$16.11 -25.4%
Earnings Power Value
High Conviction
$13.87 -35.7%
CUCE Ensemble
Medium Conviction
$16.36 -24.2%
First Chicago
High Conviction
$20.77 -3.8%

Unlock the Full Matrix

Access 9 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 13 Models →

Cancel anytime · No contracts · Instant access

What Is Nature's Sunshine Products, Inc (NATR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Nature's Sunshine Products, Inc's intrinsic value is estimated at $15.87, suggesting the stock is overvalued at its current price of $21.58. With 12 out of 13 models flagging downside (-26.5% average return), the market may be pricing in unsustainable growth. The most optimistic model, First Chicago, places fair value at $20.77 (-3.8%), while Dynamic NAV — the most conservative — estimates $6.78 (-68.6%). This +64.8% gap reflects genuine analytical uncertainty about Nature's Sunshine Products, Inc's intrinsic worth.

What Do the Models Say About NATR?

13 of 13 models are currently active for NATR. All 13 active models suggest the stock trades above fair value. The Bayesian DCF estimates NATR's intrinsic value at $16.11, implying -25.4% downside from the current price. See which stocks rank higher →

How Does NATR Rank in Pharmaceutical Preparations?

Among 440 Pharmaceutical Preparations stocks, NATR ranks #23 by Quality of Company score. CirclFi's QOC score of 8.5/10 evaluates 32 fundamental signals. A score of 8.5 places NATR in the top tier.

See all Most Undervalued Pharmaceutical Preparations Stocks →

Within the Pharmaceutical Preparations space, Nature's Sunshine Products, Inc competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is NATR a Value Trap?

CirclFi's Value Trap algorithm assigns NATR a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

13 of 13 models are active for Nature's Sunshine Products, Inc. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Nature's Sunshine Products, Inc is rated at 8.5/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.

The gap between the most bullish and bearish model spans +64.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NATR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NATR's 13 active models, average confidence is 48%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Nature's Sunshine Products, Inc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Nature's Sunshine Products, Inc

What is Nature's Sunshine Products, Inc's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Nature's Sunshine Products, Inc (NATR) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $16.11. The Quality of Company score is 8.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NATR overvalued or undervalued right now?

At $21.58, 0 of 13 active models suggest NATR may be undervalued, while 13 indicate potential overvaluation. The assessment depends on which methodology best fits Nature's Sunshine Products, Inc's business model in Pharmaceutical Preparations.

What does a Quality of Company score of 8.5 mean for NATR?

Nature's Sunshine Products, Inc's QOC of 8.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on NATR?

CirclFi analyzes NATR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 13 of 13 are active for this stock. Read the full methodology →

Is NATR a value trap in 2026?

Nature's Sunshine Products, Inc's Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 13 mathematical frameworks give you clarity on NATR.

Unlock All 13 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access